Additionally, the HER2-zero group may include a subset of triple-negative breast cancers, which more frequently exhibit necrosis and stromal edema, potentially contributing to further variability in PD-Δ% and reinforcing intragroup heterogeneity (27). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.